Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ariad opts for genome profiling to advance NSCLC product

This article was originally published in Clinica

Executive Summary

In a bold move Massachusetts-based Ariad Pharmaceuticals is partnering with Foundation Medicine, a molecular information company, to use genomic profiling to identify the optimal patient population for its investigational non-small cell lung cancer drug AP26113. Even though genomic profiling has been available for some time, few companies have used it to develop their regulatory approval submissions.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT099649

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel